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Abstract 
Increasing incidence and poor outcome of chronic non-communicable diseases in western population would 
require a paradigm shift in the treatments. Guidelines-based medical approaches continue to be the standard rule 
in clinical practice, although only less than 15% of them are based on high-quality research. For each person who 
benefits from the 10 best-selling drugs in the USA, a number between 4 and 25 has no one beneficial effect. 
The reductionist linear medicine method does not offer solutions in the non-manifest preclinical stage of the 
disease when it would still be possible to reverse the pathological progression and the axiom "a drug, a target, a 
symptom" are still inconclusive. Needs additional tools to address these challenges.  
System Medicine considers the disease as a dysregulation of the biological networks that changes throughout the 
evolution of the pathological process and with the comorbidities development. The strength of the networks 
indicates their ability to withstand dysregulations during the perturbation phases, returning to the state of stability. 
The treatment of dysregulated networks before the symptomatological manifestation emerges offers the possibility 
of treating and preventing pathologies in the preclinical phase and potentially reversing the pathological process, 
stopping it or preventing comorbidities. Furthermore, treating shared networks instead of individual phenotypic 
symptoms can reduce drug use, offering a solution to the problem of ineffective drug use. 
 
 
 
 
 
Introduction 
 
The reductionist linear medicine has 
undoubtedly contributed to the prolongation of the life 
expectancy of the western population, but, as far as 
chronic non-communicable diseases are concerned, it 
presents some problems that require a paradigm shift 
in the treatments currently in use. 
The progressive ageing of the population and 
the increase in environmental pollution are conditions 
capable to profoundly influencing the health status of 
the population. 
The management of non-communicable 
diseases, the ageing of the population and the 
progressive environmental pollution, pose new and 
complex problems, difficult to be solved by the current 
health organisation, also due to the economic 
sustainability of the care [1], [2], [3]. 
The incidence of complex non-communicable 
diseases, such as type II diabetes, cardiovascular 
diseases (growing exponentially), atopic dermatitis 
and cancer, increases with age, but the most worrying 
fact is that it is also increasing in the pediatric 
population [4], [5], [6], [7], [8]. 
Also, regarding transmissible pathologies, 
there are new challenges related to the increasing 
resistance of microbes to antibiotics and to the limited 
number of new drugs being developed [9], [10], [11]. 
Guidelines-based medical approaches 
continue to be the rule in clinical practice, although 
only less than 15% of them are based on high-quality 
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research. Although this type of (statistical) approach 
can be profitable in the general population, it becomes 
unsuccessful when compared to the genetic, 
epigenetic and environmental characteristics of the 
individual subject [4].
 
The result is excessive 
healthcare spending compared to poor results. The 
annual cost of ineffective treatments in the US would 
be $ 350 billion, while the development of new linear 
drugs costs $ 1 billion for each formulation, with an 
additional impact on the cost of health care [12]. 
In research on the 10 best-selling drugs in the 
USA, it was found that, for each person who benefits 
from one of these treatments, a number between 4 
and 25 has none [13]. 
Another study showed that the use of 
prescription drugs has drastically increased among 
the elderly population during an observation period of 
12 years and, in particular, the number of patients 
taking more than 5 drugs has increased from 12.8% at 
39.0% from 1988 to 2010, identifying a population 
considered particularly fragile [14]. 
Usually, in chronic conditions, Western 
Medicine treats the symptomatic manifestations of the 
disease (e.g. hypertension or hypercholesterolemia) 
and often can identify patients at risk in advance. 
However, this method does not offer solutions in the 
non-manifest preclinical stage of the disease, when it 
would still be possible to reverse the pathological 
progression, correcting underlying causes [12], [13], 
[14], [15]. 
It, therefore, appears clear that the need for 
additional tools to address these challenges. For this 
reason, more and more frequently, System Medicine 
is proposed as a useful tool [16], [17], [18], [19], in 
particular in terms of different view and approach to 
the disease, unfortunately even more in theory than in 
practice, because the alternatives to the axiom "a 
drug, a target, a symptom" are still struggling to get 
ahead. 
The Bioregulatory System Medicine (BrSM), 
the subsequent evolution of Systems Medicine, aims 
to bridge this gap through the use of low dose 
medicines with precise, targeted and synergistic 
bioregulatory capacities. These are medicines 
composed of different therapeutic nuclei (multi-
component) with an effect on as many different 
targets (multi-target) and a favourable safety profile 
[20], [82]. Based on a correct evaluation of the 
patient's clinical history, recognition of its 
characteristics specific and at the stage of progression 
of the pathology, the BrSM directs the choices of 
therapeutic strategy, allowing a more complete and 
systematic approach to the patient. 
 
 
 
Systems Medicine 
 
Biological systems have some aspects in 
common, including self-organisation, intrinsic stability, 
robustness and resilience [12], [15], [21]. 
Self-organisation is one of the fundamental 
characteristics of Systems Medicine and takes up the 
so-called autopoiesis of the school of Santiago de 
Francisco Varela and Humberto Maturana [21], [22].  
The complexity of the human body is 
considered as a set of interconnected networks, 
composed of genome, molecules, cells, organs, going 
beyond, up to the environment surrounding the 
organism and to the networks created by individuals in 
societies [4], [12]. 
The disease is considered a dysregulation of 
the networks, linked to different perturbations or 
disturbances that act by jeopardising stability and 
functionality [23], [24], [25]. 
The networks go through phases of 
dysregulation long before the recognisable pathology 
divides, and before any structural symptoms or 
alterations appear. 
Stability is another intrinsic characteristic of 
complex systems, and in living organisms, it is 
ensured by self-regulation to maintain homeostasis. 
The networks are organised in functional 
modules to protect the system from global collapse, 
and robustness (i.e. the ability of systems to resist, 
without modification, to perturbations) allows the 
system to defend itself against elements of 
disturbance and destabilisation [15], [26]. 
Finally, resilience indicates the ability of the 
system to withstand disturbances by adapting to it to 
guarantee the function of the system itself. 
These characteristics can be exploited in the 
clinical approach and the BrSM aims at this goal, 
placing as the main goal of the therapy the support to 
the organism self-regulation system to re-establish a 
normal state of homeostasis or, if this is not possible, 
a state of optimal compensation, reducing the use of 
drugs as much as possible [20]. 
In practice, numerous distinctive aspects 
differentiate the Systems Medicine from the linear 
reductionist approach [4], [16], [81]. 
The use of targeted drug therapies that target 
only one point of the network, as happens in 
reductionist medicine, has been questioned. If the 
interrelations of the target are not taken into account, 
in fact, one risks unintentionally causing the opposite 
effect. For example, the use of statins could increase 
atherosclerosis due to the depletion of coenzyme Q10 
and vitamin K2, 25 or the use of non-steroidal anti-
inflammatory drugs in acute inflammation has an anti-
inflammatory effect, but also tends to block the 
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production of prostaglandins (PG) E2, necessary for 
the activation of lipid mediators responsible for 
resolving inflammation and triggering the repair and 
restoration processes of tissue physiology [28], [29], 
[30]. 
The recognition of the role of the 
dysregulation of biological networks in the evolution of 
pathologies not only offers opportunities for their 
management but also questions the current diagnostic 
procedure, based on a fixed number of biomarkers 
that are interpreted only after the onset of clinical 
symptoms [31], [32]. This different approach to the 
patient, called Network Medicine, has many 
advantages [12]. 
According to this more current reference 
model, in the diagnosis phase we tend to recognize 
dynamic patterns in network dysregulations rather 
than resort to isolated and immutable biomarkers over 
time and, in particular, in the approach to the 
progressive evolution of the pathology, such patterns 
contribute to the definition of an individualized vision 
for each patient [17], [33], [34]. 
In 2008 Fuite et al., showed him that, through 
the analysis of a genomic network in patients with 
chronic fatigue syndrome, it was possible to identify 
an alteration in the interrelation of the immune system, 
adrenocorticotropic hormone, and thyroid [35]. 
More recently, recognition of specific patterns 
in patients with systemic sclerosis has allowed 
physicians to predict prognosis and contributed to the 
definition of therapy [36]. 
To examine and visualise these complex 
networks to define their patterns, the so-called "-
omics" technologies are used: genomics, 
epigenomics, proteomics, metabolomics and 
microbiomics, up to the most recent exposomics [10], 
[19], [37]. It appears very promising, in this panorama, 
also the alterations of the parameters of bio-
impedance metre that involve the analysis of the 
systems [38].
 
The reductionist approach tends largely to 
ignore environmental influences, but starting from the 
revolutionary article by Christopher Wild, who 
introduced the term esposoma in 2005, this concept 
has taken on a prominent role in the systems 
approach [10], [39], [40], [41]. 
The concept of exposome indicates the list of 
all the chemical substances to which a subject has 
been and including environmental, food or work-
related, endogenous biochemical substances formed 
by normal metabolic processes, and by inflammation, 
oxidative stress, lipid peroxidation and infections, as 
well as other natural metabolic processes, such as 
alteration of the intestinal microbiome [41]. These 
exhibits affect all networks and in particular the 
epigenetic one. 
The omics technologies are also ideally useful 
for investigating the effects of multicomponent / 
multitarget drugs with bioregulation properties, as they 
would allow clarifying the effects effects [42] better. 
In summary, System Medicine considers the 
disease as a dysregulation of the biological networks 
that changes throughout the evolution of the 
pathological process and with the development of 
comorbidities. The strength of the networks indicates 
their ability to withstand dysregulations during the 
perturbation phases, returning to the state of stability 
or guaranteeing the best possible stability through 
compensation mechanisms [5], [24], [43], [44]. 
The treatment of dysregulated networks 
before the symptomatological manifestation emerges 
offers the possibility of treating and preventing 
pathologies in the preclinical phase and potentially 
reversing the pathological process, stopping it or 
preventing comorbidities [15]. 
Furthermore, treating shared networks 
instead of individual phenotypic symptoms can reduce 
drug use, offering a solution to the problem of 
ineffective drug use [4]. 
 
 
Systems Bioregulation Medicine 
 
The conceptual pillar of BrSM is a therapeutic 
approach that aims to treat the networks 
dysregulations of underlying pathology by supporting 
self-regulation networks, to promote the restoration of 
physiological homeostatic conditions of networks or 
the achievement of a state of equilibrium [20].  
The dysregulation of the networks is the initial 
phase of the pathological evolution, preceding the 
symptomatological manifestation; it follows an 
advantageous overall therapeutic intervention and 
directed to the dysregulation as a whole, instead of on 
the single symptomatological manifestations of each 
disease. 
Complex non-communicable diseases often 
share dysregulations of the inflammatory and 
metabolic networks. During evolution, these same 
networks have evolved to address a wide variety of 
circumstances. At the same time, however, it must be 
considered that this characteristic of flexibility also 
makes them more vulnerable to dysregulation. The 
regulation of these networks is based on relatively 
primitive self-regulation processes and is often 
overwhelmed by incongruous lifestyles and by 
increasingly unfavourable conditions of environmental 
pollution to which modern man is exposed [45], [46]. 
The Nervous and Endocrine Systems 
maintain a systemic homeostatic state, while the local 
homeostatic circuits regulate the state and integrity of 
cell and tissue networks. However, when homeostatic 
mechanisms are not sufficient, the inflammatory 
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process is triggered in order to maintain or restore 
balance. Several authors define this process as 
homeostatic inflammation (or physiological 
inflammation [47], [48]. 
The inflammatory response of the organism 
and its effects on it in the acute phase play a 
fundamental role in the model of BrSM. The 
inflammations that persist can potentially cause 
alterations of the cellular microenvironment and 
progressively lead to structural tissue damage, up to 
their degeneration [45], [49]. In BrSM the inflammatory 
response is used as a substitute in clinical decision 
making. 
The vision of inflammation as a static process 
that ends with the elimination of its mediators has 
changed a lot in recent years. Today inflammation is 
considered an active process. As is often observed in 
homeostatic mechanisms, it is the initial mechanism 
itself that also determines its end. Among the main 
protagonists is PGE2, which is not only responsible 
for most of the symptoms associated with acute 
inflammation, but also plays a fundamental role in the 
activation of the so-called mediators favouring the 
resolution of the inflammatory process [26], [27]. 
Drugs developed linearly, such as non-
steroidal anti-inflammatory drugs, whose main target 
is cyclo-oxygenase 2, have an anti-inflammatory 
action, but can at the same time prevent the resolution 
of the problem by forcibly suppressing PGE2 [28]. 
It has recently been shown that the multi-
component drug Traumeel has a different mechanism 
of action in the context of the inflamed tissue and a 
modulation effect on PGE2 and on specialised 
prorisolutive mediators that can favour a more 
physiological resolution of the process [50], [51]. 
 
 
Individualised treatments 
 
In their pioneering article, Ahn et al., they also 
outlined the future of System Medicine in clinical 
practice [52]. 
The applications-omics bode well for a 
revolution in the approach to the diagnosis and 
individualisation of patients based on risk, stage of the 
disease and possible response to treatment. 
However, the costs and degree of innovation currently 
prevent the use of these tools as a routine medical 
practice. This means that doctors must continue to 
rely on classical methods to selectively choose the 
therapy of their patients. 
The path starts from the collection of the 
anamnesis, in which the aspects related to genetics 
and exposome deserve special attention. The 
patient's prenatal history has the same importance as 
post-birth events, as many stress factors, such as 
maternal psychological stress and exposure to 
environmental xenobiotics, have a fundamental 
impact on the patient's responses in the later stages 
of life. This is often mediated by epigenetic alterations 
[53], [54], [55]. 
Work and leisure activities can be indicative of 
possible exposures and stress factors. 
Genetic and genomic markers are often 
suggestive of possible risks; by way of example, 
single nucleotide polymorphisms may represent a risk 
factor, for example in the known association between 
homocysteine metabolism disorders and 
cardiovascular diseases [56]; another example is the 
risk assessment tests for breast cancer [57]. 
Genomics and metabolomics are also used in clinical 
practice to predict treatment responses [58]. 
This is also useful for the probabilistic 
forecasts cited by Ahn. 
The biomarkers and algorithms currently used 
to diagnose pathologies in terms of phenotypic results 
(e.g. erythrocyte sedimentation rate, high-sensitivity 
C-reactive protein and complete blood count) should 
be used appropriately for clinical decisions. 
The treatment based on the progression of 
the disease and in particular on the recognition of 
preclinical stages will remain difficult to apply until the 
sciences-omics and Networks Medicine become part 
of the common practice. 
In BrSM, the effect of the inflammatory 
response on the microenvironment is used as a 
substitute / in addition to the sciences-omics available 
for the interpretation of clinical decisions. Unlike what 
was thought in the past, the microenvironment has the 
possibility to reverse the structural alterations, 
provided that the cell membrane has not been 
damaged. 
In the BrSM there is, therefore, a dynamic 
attitude in the prescription, which will be based on the 
degree of progression of the patient's pathology. 
To further individualize the treatment, the 
patient's exposure and microbiome are considered 
and, consequently, the use of appropriate draining 
and detoxifying medicines and the insertion of certain 
probiotic strains, often specific for each pathological 
process (eg Bifidobacterium PBL1 in the metabolic 
syndrome or Bifidobacterium lactis CECT 8145, 
Bifidobacterium longum CECT 7347, and 
Lactobacillus casei CECT 9104 in atopic dermatitis) 
[59], [80]. 
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Change in therapy paradigm 
 
In the "one drug, one target, one symptom" 
approach, pharmacological treatment is often 
symptomatic or aimed at treating phenotypic results 
secondary to dysregulation. These are static 
treatments, and patients often take the same 
therapies for long periods. 
Supporting the self-regulation system, the 
BrSM aims to re-establish a state of health or 
compensation, and this means that often, once this 
result is achieved, the patient no longer needs drugs 
or needs only in limited quantities. This requires 
careful assessments of disease progression and good 
monitoring. In the case of advanced phenotypic 
alterations, drug treatment is frequently the only 
option available. Obviously, this also applies to 
diseases in which there is no possibility of regulation, 
for example in the case of ablation of an organ, and, 
in these cases, replacement therapy must be taken for 
life. 
 
 
Low dose drugs effects 
 
This characteristic does not exclusively refer 
to the attempt to reduce the use of drugs to the 
minimum necessary, which can be the result of better 
individualisation of the patient or improvement of the 
state of health through the achievement of optimal 
self-regulation. 
The hormetic effects of the substances are 
the subject of constant research [60]. The hormesis 
seems to have positive consequences on the 
resilience of the organism, in particular through the 
so-called mitormesis [slight mitochondrial damage can 
induce a hormetic response (mitormesis) that 
promotes compensatory adaptive processes] [61], 
[62], [63].  
Some authors have specifically cited the 
hormetic effects that increase adaptive responses 
through the exposure of natural phytotherapeutic 
substances (xenormes) [64]. 
This is a concept that requires further 
research but could be a plausible hypothesis to 
explain how some substances in reduced 
concentrations exert bioregulation effects. 
The low naltrexone dose, which has been 
discussed earlier, is a good example of how a drug to 
conventional doses, developed with a specific 
purpose, can also be used for other purposes. It is 
able, at this lower dosage, to generate bioregulatory 
effects. This also happens for other preparations with 
bioregulation properties: for example, the medicinal 
product Lymphomyosot, originally developed for 
lymphatic pathology, has subsequently shown that it 
can also be usefully used for wound healing [65].
 
 
Since-omic technologies allow the analysis of 
large groups of data on multitarget actions; the 
identification of alternative applications of drugs is 
destined to grow over time. 
 
 
Synergistic treatments 
 
To achieve bioregulation in dysregulations 
involving more than one network or different functional 
modules of a network, it may be necessary to resort to 
a combination of several drugs (treatments). 
This is a common approach in the BrSM, in 
particular for chronic diseases, in which with the 
development of comorbidities we are witnessing the 
subsequent dysregulation of further networks. 
Chronic diseases seem to have in common 
the main dysregulation of certain networks [66], [67], 
[83]. These include the network inflammatory, the 
network metabolic, the network energy-mobile, and 
network neuroendocrine.  
The chronic dysregulation of the networks 
also puts a strain on the processes of self-regulation. 
It is, therefore, necessary to add cofactors to optimise 
the efficient operation of enzymes, for example, since 
they can run out if they are not reintegrated over time. 
The patient's nutritional status must be carefully 
considered and, about it, deficient cofactors will be 
established according to specific needs.  
As mentioned above, some pharmacological 
therapies also lead to the depletion of cofactors that 
are fundamental for self-regulation (e.g. coenzyme Q 
10 and vitamin K2 in statin-based therapies) [25]. 
Missing cofactors must be adequately replenished 
and, if bioregulation allows it, the patient must 
gradually reduce and then stop therapy. 
Recently the efficacy of a combination of two 
drugs with bioregulatory properties and their 
synergistic effects in the treatment of knee 
osteoarthritis (Arnica comp. + Zeel T) has been 
demonstrated [68], [69], [70]. 
 
 
"Space - sensitive" treatments: 
administration of drugs in specific 
locations 
 
As can be seen from the bioregulation model, 
the microenvironment plays a fundamental role in the 
therapeutic approach of the BrSM. In numerous 
Global Dermatology 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
3058                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
publications, it is argued that connective tissue is an 
organ with interconnecting properties [71], [72].
 
A 
recent publication in Nature even speaks of interstitial 
spaces containing fluidly plastic structures previously 
not characterised, emphasising the fundamental 
function of this important tissue and introducing for it 
the most correct classification of the organ [73]. 
Drugs can be administered directly in this 
organ through infiltration techniques at specific points. 
In fact, injection into the acupuncture points is 
frequent in the BrSM approach [74], [75], [76], [77]. 
Intradermal injections are also used in Aesthetic 
Medicine, similarly to infiltration in the corresponding 
dermatomes to act on the internal organs [78], [79]. 
 
 
Conclusions 
 
In the current context, medical personnel are 
exposed to numerous challenges, which require new 
tools to respond to patients' needs. 
The Systems Medicine approach is making 
headway in clinical practice as a solution for improving 
patient management; however, the reference 
paradigm of conventional therapies "a target, a drug" 
is proving not entirely suitable. 
System Medicine applications, such as BrSM, 
aim to remedy the shortcomings of the conventional 
approach, using complex multicomponent drugs, to 
obtain regulatory effects on multiple targets.  
The BrSM complies with the fundamental 
criteria that distinguish the Systems Medicine 
approach, but the clear therapeutic objective is the 
support of patient self-regulation networks. This 
approach can be associated with "linear drugs" based 
on the specific needs of patients. Applying these 
different approaches at the same time, we will witness 
the birth of a single Medicine: the one that responds to 
the specific patient's needs at a specific time. 
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